

111. The composition of claim 74, 75, or 76, wherein the composition contains a pharmaceutically effective carrier for the oral delivery of the composition.

112. The composition of claim 77, wherein the composition contains a pharmaceutically effective carrier for the oral delivery of the composition.

113. The composition of claim 74, 75, or 76, wherein the composition contains a pharmaceutically effective carrier for the topical delivery of the composition.

114. The composition of claim 77, wherein the composition contains a pharmaceutically effective carrier for the topical delivery of the composition.--

PRELIMINARY REMARKS

I. Amendment to the Specification

Amendment to the specification is made to bring the disclosure of particular nucleic acid and amino acid sequences, and the Sequence Listing itself in line with 37 C.F.R. §1.821(c). A computer readable form of the Sequence Listing in accordance with 37 C.F.R. §1.821(e) is concurrently submitted herewith. The content of the paper copy and computer readable forms are the same as required under 37 C.F.R. §1.821(f). The addition of the Sequence Listing necessitates renumbering subsequent pages in the application. Renumbering of the pages in the claims and abstract is requested to maintain clarity in the order of the application and adds no new matter to the application.

If the Examiner believes that submission of a substitute specification incorporating the above-requested amendments would materially facilitate handling by the Patent Office, telephone advice of the same to the undersigned would be appreciated.

II. Amendment to the Claims

Support for the claims 71-114 is found throughout the specification. Specifically, support for the recombinant SCF and SCF fragments recited in claims 71-76 is found in canceled claim 39, Fig. 15C, 42A-D, 44A-C and also found variously on page 182, beginning on line 30 (1-100, 1-110, 1-120, 1-123, 1-127, 1-130, and 1-133), page

182, beginning on line 10 (1-137, 1-141, 1-145, 1-148, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-162, 1-163, 1-166, 1-168, 1-173, and 1-178), page 93, line 11 (1-164), page 183 beginning on line 7 (2-164, 5-164, and 11-164), page 183 beginning on line 34 (1-180, 1-185, 1-188, and 1-189), page 184 beginning on line 7 (1-152 and 1-157), page 93, line 12 (1-183) page 184 beginning on line 9 (1-165 and 2-165) and on page 184, line 2 (1-220). Support for the recited SCF fragments in claim 73 is found on page 185, lines 12-13.


Support for compositions of SCF polypeptides of claims 71 -114 is found throughout the application. Support for pharmaceutical compositions containing is specifically found on page 24, line 26 through page 26, line 5. Support for modified and/or conjugated SCF polypeptides such as pegylated SCF is found in Example 13, page 135, line 6 through page 138, line 8. Use of SCF polypeptides in combination with other cytokines is discussed throughout the application especially on page 27, line 1 through line 7; in Example 21, page 156, line 9 through page 160, line 33; in Example 22, page 161, line 1 through page 164, line 7; in Example 24, page 168, line 18 through page 170, line 27; in Example 25, page 170, line 29 through page 175, line 35; and in Example 26, page 176, line 1 through page 179, line 28. Support for the production and characterization of SCF analogs and fragments is found in Example 28, page 182-185.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

Attorneys for Applicant(s)
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By


David W. Clough
(Reg. No. 36,107)

Chicago, Illinois
December 31, 1998